The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict DepoMed's revenues will increase 119.6% and EPS will remain in the red.
The average estimate for revenue is $26.6 million. On the bottom line, the average EPS estimate is -$0.11.
Last quarter, DepoMed recorded revenue of $33.3 million. GAAP reported sales were much higher than the prior-year quarter's $16.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.03. GAAP EPS were -$0.03 for Q3 compared to -$0.15 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 94.7%, 170 basis points better than the prior-year quarter. Operating margin was -4.6%, 5,170 basis points better than the prior-year quarter. Net margin was -4.5%, 4,740 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $90.9 million. The average EPS estimate is -$0.58.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 232 members out of 251 rating the stock outperform, and 19 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 50 give DepoMed a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on DepoMed is buy, with an average price target of $9.38.
- Add DepoMed to My Watchlist.